SDG 3. GOOD HEALTH & WELL-BEING Exscientia

Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb

OXFORD, England–(BUSINESS WIRE)–Exscientia, the clinical stage, Artificial Intelligence (AI)-driven pharmatech company, announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY). This expanded collaboration has the potential to add to the Bristol Myers Squibb drug pipeline whilst enhancing Exscientia’s portfolio of shared assets. The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates in mul






Read more on Business Wire Technology News

You may also like

Comments are closed.